Guardant Health Q1 revenue $203.5M (+21% YoY); raises FY2025 revenue guidance to $880-$890M

Guardant Health, Inc.

2025-Q1 EPS reported -$0.77 revenue$203,471,000

Q1 total revenue $203.5M, +21% YoY; oncology $150.6M (+20%, 59K tests); screening $5.7M (9K Shield tests); biopharma $45.4M (+21%).
Net loss $95.2M ($0.77/sh) vs $115.0M loss year ago; non-GAAP net loss $61.1M ($0.49/sh); cash $803.9M.
FY2025 revenue guidance raised to $880-$890M (+19-20% YoY) from $850-$860M; screening revenue guided $40-$45M (from $25-$30M).
Non-GAAP gross margin guided 62-63%; FCF burn expected $225-$235M; ex-screening business on track for FCF breakeven in Q4 2025.
Shield received CMS ADLT status ($1,495/test) and VA network coverage covering 9M lives; launched upgraded Guardant360 Tissue test.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.